Form 4: Artivion Director Marna Borgstrom Awarded 7,850 Shares

Artivion, Inc. director Marna P. Borgstrom received a grant of 7,850 restricted stock units as part of the company's annual equity incentive program.

Summary

• Marna P. Borgstrom, a member of the Board of Directors, was granted 7,850 shares of common stock on May 14, 2026.
• The grant consists of Restricted Stock Units (RSAs) that are scheduled to vest in full on May 14, 2027.
• Following this transaction, Borgstrom directly owns a total of 56,938 shares of Artivion, Inc.
• The shares were awarded at a price of $0.00 as part of the company's Equity and Cash Incentive Plan.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral, routine administrative filing related to standard board compensation that does not signal a change in company fundamentals.

Positives

• Director compensation is heavily weighted toward equity, aligning board interests with those of long-term shareholders.
• The reporting person has maintained a significant ownership stake, now totaling 56,938 shares.
• The one-year vesting cliff ensures continued service and commitment from the director through at least mid-2027.

Negatives

• The issuance of new shares under incentive plans results in minor dilution for existing shareholders.

Risks

• The ultimate value of the compensation is subject to market volatility and the company's stock performance over the next 12 months.
• Vesting is contingent upon the director's continued service through the vesting date of May 14, 2027.

Future Outlook

The director is expected to remain on the board through at least May 2027 to satisfy the vesting requirements of the newly granted equity.

Management Comments

• The RSA grant vests on May 14, 2027, pursuant to the terms of the Equity and Cash Incentive Plan.

Industry Context

StockSavvy.ai notes that Artivion's use of annual equity grants for non-employee directors is consistent with standard corporate governance practices in the medical technology and healthcare sectors to attract and retain high-quality board oversight.

Comparison to Industry Standards

• The grant size is typical for mid-cap medical device companies where director compensation often ranges between $150,000 and $250,000 annually, split between cash and equity.
• Artivion's vesting schedule of one year for director RSAs is a standard benchmark compared to peers like Merit Medical Systems or Haemonetics.

Corporate Governance

Related Party Transactions

• Grant of equity to a director as part of a standard compensation package.

Stakeholder Impact

• Shareholders may see minor dilution from the issuance of new shares.
• The board of directors maintains a vested interest in the company's long-term stock price performance.

Next Steps

• Vesting of the 7,850 shares on May 14, 2027.

Key Dates

Recommendation

This filing is a routine disclosure of director compensation and does not provide new material information regarding the company's operational performance or strategic direction that would warrant a change in investment rating.

Keywords

Artivion, AORT, Insider Trading, Director Compensation, Restricted Stock Units, Equity Incentive Plan, Marna Borgstrom